Gossamer Bio Inc
For the period ended Jun 30, 2024. Filed Aug 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 12, 2024
GOSS$10.65+9.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Exhibit Index
| ExhibitNumber · Exhibit Description · Incorporated by Reference · Filed Herewith | |||||
|---|---|---|---|---|---|
| Form · Date · Number | |||||
| 3.1 | Amended and Restated Certificate of Incorporation, as amended. | 10-Q | 8/8/2023 | 3.1 | |
| 3.2 | Amended and Restated Bylaws. | 10-Q | 5/12/2020 | 3.2 | |
| 4.1 | Form of Common Stock Certificate. | S-1/A | 1/23/2019 | 4.1 | |
| 4.2 | Amended and Restated Investors’ Rights Agreement, dated July 20, 2018, by and among the Registrant and certain of its stockholders. | S-1 | 12/21/2018 | 4.2 | |
| 4.3 | Indenture, dated as of May 21, 2020, by and between the Company and Wilmington Trust, National Association. | 8-K | 5/21/2020 | 4.1 | |
| 4.4 | First Supplemental Indenture, dated May 21, 2020, by and between the Company and Wilmington Trust, National Association. | 8-K | 5/21/2020 | 4.2 | |
| 4.5 | Form of Global Note representing 5.00% Convertible Senior Notes due 2027 (included as part of Exhibit 4.4). | 8-K | 5/21/2020 | 4.3 | |
| 4.6 | Form of Warrant | 8-K | 7/20/2023 | 4.1 | |
| 10.1† | Collaboration and License Agreement dated May 3, 2024 by and among GB002, Inc., Gossamer Bio 002 Ltd. and Gossamer Bio, Inc. on the one hand and CHIESI Farmaceutici S.p.A and CHIESI USA, Inc. on the other hand. | X | |||
| 31.1 | Certification of Chief Executive Officer of Gossamer Bio, Inc., as required by Rule 13a-14(a) or Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | X | |||
| 31.2 | Certification of Chief Financial Officer of Gossamer Bio, Inc., as required by Rule 13a-14(a) or Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | X | |||
| 32.1* | Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | X | |||
| 32.2* | Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | X | |||
| 101.INS | XBRL Report Instance Document | X | |||
| 101.SCH | XBRL Taxonomy Extension Schema Document | X | |||
| 101.CAL | XBRL Taxonomy Calculation Linkbase Document | X | |||
| 101.LAB | XBRL Taxonomy Label Linkbase Document | X | |||
| 101.PRE | XBRL Presentation Linkbase Document | X | |||
| 101.DEF | XBRL Taxonomy Extension Definition Linkbase Document | X | |||
| † | Portions of this exhibit (indicated by asterisks) have been omitted for confidentiality purposes pursuant to Item 601(b)(10)(iv) of Regulation S-K. |
|---|---|
| * | This certification is deemed not filed for purpose of section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.